Current Rating Overview
MarketsMOJO’s Buy rating for Artemis Medicare Services Ltd is supported by a comprehensive assessment across four key parameters: Quality, Valuation, Financial Trend, and Technicals. The company’s Mojo Score stands at 78.0, reflecting a strong overall profile. This score represents a significant improvement from the previous grade of Hold, which was assigned before 08 June 2026. Investors should note that all data and performance indicators discussed here are as of 04 August 2026, ensuring a current and relevant perspective.
Quality Assessment
Artemis Medicare Services Ltd demonstrates a solid quality grade, underpinned by its robust operational and financial health. The company maintains a low Debt to EBITDA ratio of 1.39 times, signalling a strong ability to service its debt obligations without undue strain. This conservative leverage position reduces financial risk and supports sustainable growth. Additionally, the company has reported positive results for ten consecutive quarters, highlighting consistent operational performance and resilience in a competitive hospital sector.
The Return on Capital Employed (ROCE) for the half-year period is a healthy 14.21%, indicating efficient use of capital to generate profits. The Debt-Equity ratio remains low at 0.28 times, further reinforcing the company’s prudent capital structure. Moreover, the operating profit to interest coverage ratio of 8.74 times reflects ample earnings to cover interest expenses, a key indicator of financial stability.
Valuation Perspective
From a valuation standpoint, Artemis Medicare Services Ltd is considered attractive. The stock trades at a Price to Book Value of 5.1, which, while elevated, is justified by the company’s growth prospects and profitability metrics. Importantly, the stock is currently trading at a discount relative to its peers’ average historical valuations, offering investors a favourable entry point.
The company’s Return on Equity (ROE) stands at 11.3%, reflecting solid profitability for shareholders. Over the past year, the stock has delivered a return of 21.74%, outpacing many competitors in the hospital sector. Profits have grown by 28.2% during the same period, resulting in a Price/Earnings to Growth (PEG) ratio of approximately 4. While this PEG ratio suggests a premium valuation, it is supported by the company’s consistent earnings growth and market-beating returns.
Financial Trend and Growth
Artemis Medicare Services Ltd exhibits a positive financial trend, with operating profit growing at an impressive annual rate of 59.20%. This rapid expansion in profitability underscores the company’s ability to scale operations effectively and capitalise on market opportunities. The steady improvement in key financial ratios and sustained profit growth over recent quarters provide a strong foundation for future performance.
Market returns further validate this trend. The stock has generated a 41.32% return over the past six months and a 21.52% gain over three months, demonstrating strong momentum. Year-to-date returns of 11.81% and a one-year return of 21.74% highlight the company’s capacity to deliver consistent shareholder value in both short and long-term horizons.
Technical Analysis
Technically, Artemis Medicare Services Ltd is rated bullish. The stock’s price action reflects positive investor sentiment and strong buying interest. The recent day change of +0.28% on 04 August 2026 adds to the evidence of steady upward movement. Over the past week, the stock has gained 9.31%, and over the last month, it has appreciated by 16.36%, signalling robust technical strength.
Such bullish technical indicators often suggest that the stock is well-positioned to continue its upward trajectory, supported by favourable market dynamics and company-specific catalysts. Investors monitoring technical trends may find this an encouraging sign for potential entry or accumulation.
Summary for Investors
In summary, the Buy rating for Artemis Medicare Services Ltd reflects a balanced and data-driven evaluation of the company’s current standing. The combination of strong quality metrics, attractive valuation relative to peers, positive financial trends, and bullish technical signals provides a compelling case for investors considering this stock. While the rating was updated on 08 June 2026, the detailed analysis here is based on the latest data as of 04 August 2026, ensuring that investment decisions are informed by the most recent information available.
Investors should consider this rating as an endorsement of the company’s potential to deliver sustainable returns, supported by solid fundamentals and market performance. As always, it is prudent to monitor ongoing developments and market conditions that may impact the stock’s trajectory.
Fresh entry alert! This Small Cap from Electronics & Appliances sector is already turning heads in our Top 1% club. Get ahead of the market now!
- - New Top 1% entry
- - Market attention building
- - Early positioning opportunity
Long-Term Market Performance
Artemis Medicare Services Ltd has demonstrated market-beating performance not only in the recent past but also over longer periods. The stock has outperformed the BSE500 index over the last three years, one year, and three months, underscoring its resilience and growth potential within the hospital sector. This consistent outperformance is a testament to the company’s strategic positioning and operational execution.
Such sustained returns are particularly noteworthy for a small-cap company, which often faces greater volatility and market challenges. Artemis Medicare’s ability to deliver superior returns while maintaining strong financial health and valuation metrics makes it an attractive proposition for investors seeking growth opportunities in healthcare services.
Risk Considerations
While the Buy rating is supported by strong fundamentals and technicals, investors should remain mindful of sector-specific risks and broader market conditions. The hospital sector can be influenced by regulatory changes, healthcare policy shifts, and competitive pressures. Additionally, the relatively high Price to Book Value and PEG ratio suggest that the stock is priced for growth, which may entail some valuation risk if growth expectations are not met.
Therefore, a balanced approach that considers both the upside potential and inherent risks is advisable. Continuous monitoring of quarterly results, debt levels, and market trends will be essential to ensure the investment thesis remains intact.
Conclusion
Artemis Medicare Services Ltd’s current Buy rating by MarketsMOJO reflects a well-rounded assessment of its quality, valuation, financial trends, and technical outlook as of 04 August 2026. The company’s strong debt servicing ability, attractive valuation relative to peers, robust profit growth, and positive price momentum combine to present a compelling investment case. This rating serves as a guide for investors seeking exposure to a fundamentally sound and technically supported stock within the hospital sector.
As always, investors should align their portfolio decisions with their risk tolerance and investment horizon, using this rating as one of several tools in their decision-making process.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
